Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Induction but not inhibition of COX-2 confers human lung cancer cell apoptosis by celecoxib
Authors
Keywords
-
Journal
JOURNAL OF LIPID RESEARCH
Volume 54, Issue 11, Pages 3116-3129
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2013-08-14
DOI
10.1194/jlr.m042283
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- COX-2 inhibitors block chemotherapeutic agent-induced apoptosis prior to commitment in hematopoietic cancer cells
- (2011) Claudia Cerella et al. BIOCHEMICAL PHARMACOLOGY
- Lung Cancer Chemoprevention with Celecoxib in Former Smokers
- (2011) Jenny T. Mao et al. Cancer Prevention Research
- Inhibitory effect of celecoxib in lung carcinoma by regulation of cyclooxygenase-2/cytosolic phospholipase A2 and peroxisome proliferator-activated receptor gamma
- (2011) Ming Zhang et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Arachidonoyl ethanolamide (AEA)-induced apoptosis is mediated by J-series prostaglandins and is enhanced by fatty acid amide hydrolase (FAAH) blockade
- (2011) Christian Kuc et al. MOLECULAR CARCINOGENESIS
- The inhibitory effect of celecoxib on mouse hepatoma H22 cell line on the arachidonic acid metabolic pathwayThis paper is one of a selection of papers published in this special issue entitled “Second International Symposium on Recent Advances in Basic, Clinical, and Social Medicine” and has undergone the Journal's usual peer review process.
- (2010) Zhigang Xu et al. Biochemistry and Cell Biology
- Biological Activity of Celecoxib in the Bronchial Epithelium of Current and Former Smokers
- (2010) E. S. Kim et al. Cancer Prevention Research
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- The role of NF-κB and PPARγ in experimentally induced colorectal cancer and chemoprevention by cyclooxygenase-2 inhibitors
- (2010) Vivek Vaish et al. TUMOR BIOLOGY
- Peroxisome Proliferator-Activated Receptor- Contributes to the Inhibitory Effects of Embelin on Colon Carcinogenesis
- (2009) Y. Dai et al. CANCER RESEARCH
- Cellular membranes function as a storage compartment for celecoxib
- (2009) Thorsten J. Maier et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Activation of macrophage peroxisome proliferator-activated receptor-γ by diclofenac results in the induction of cyclooxygenase-2 protein and the synthesis of anti-inflammatory cytokines
- (2009) Samir S. Ayoub et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism
- (2009) H. A. Elrod et al. MOLECULAR CANCER THERAPEUTICS
- The anti-proliferative potency of celecoxib is not a class effect of coxibs
- (2008) Susanne Schiffmann et al. BIOCHEMICAL PHARMACOLOGY
- PPAR is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells
- (2008) M. Schwab et al. CARCINOGENESIS
- 15-deoxy-delta 12,14-prostaglandin J2inhibits the synthesis of the acute phase protein SIP24 in cartilage: Involvement of COX-2 in resolution of inflammation
- (2008) Valentina Ulivi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203
- (2008) Martin J. Edelman et al. JOURNAL OF CLINICAL ONCOLOGY
- R(+)-Methanandamide-Induced Apoptosis of Human Cervical Carcinoma Cells Involves A Cyclooxygenase-2-Dependent Pathway
- (2008) Karin Eichele et al. PHARMACEUTICAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More